Eva Rohde, Austria

Eva Rohde is Head of the Department of Transfusion Medicine at the University Hospital of the Paracelsus Medical University in Salzburg, Austria. She is Director and Qualified Person of the GMP Unit in Salzburg, which has achieved the pharmaceutical manufacturing authorization for MSC and MSC-EVs in 2015 and participated a clinical trial testing MSCs in multiple sclerosis. Recently, the team got approval for the first-in-human clinical trial “Extracellular Vesicle-enriched Secretome Fraction (VSF1.01) for the Reduction of Cochlear Implant Surgery Related Trauma (ESCRT). An open-label monocentric phase I/IIa pilot study to investigate the safety of intracochlear application of VSF1.01 enriched with hUC-MSC-EVs in patients receiving cochlear implantation” https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-512498-29-00   or clinicaltrials.gov ID: NCT06545175.

Since 2019 Eva Rohde chairs the ISEV - Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics https://www.isev.org/rigor-standardization .

Recently, she joined the newly founded Ludwig Boltzmann Institute for Nanovesicular Precision Medicine (LBI NVPM) in Salzburg (https://nvpm.lbg.ac.at/ ).

The Science-Medical-Public Liaison program at the LBI NVPM, organized by Eva Rohde aims to promote the clinical evaluation of Nanovesicular Therapeutics (NVT) by building a bridge between patients’ needs, the opportunities and challenges of clinical research, legal requirements and the broader society. The growing interest in extracellular vesicles (EV) and other nanovesicular modalities as novel therapeutic entities underscores the need for increased pre-clinical and clinical investigations, standardization, and interdisciplinary coordination of NVT drug development efforts.

https://orcid.org/0000-0001-8692-886X